Prospective trial on topotecan salvage therapy in primary CNS lymphoma

Annals of Oncology

Volumn 17, Issue 7, 2006, Pages 1141-1145

  Fischer, Lars ^a   Thiel, E ^a   Klasen, H A ^b   Birkmann, J ^c   Jahnke, K ^a   Martus, P ^a   Korfel, A ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b PIUS HOSPITAL   (Germany)

^c KLINIKUM NÜRNBERG   (Germany)

Author keywords

PCNSL; Salvage therapy; Topotecan

Indexed keywords

ANTIFUNGAL AGENT; CORTICOSTEROID; TOPOTECAN;

ADULT; AGED; ANEMIA; ARTICLE; ASPERGILLOSIS; BLOOD TOXICITY; BRAIN RADIATION; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER REGRESSION; CANCER RELAPSE; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG INFUSION; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; HYPOKALEMIA; INFECTION; LEUKOPENIA; LYMPHOMA; MALE; MONOTHERAPY; MULTICENTER STUDY; NEUROTOXICITY; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARALYTIC ILEUS; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PNEUMONIA; POLYNEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RECURRENT CANCER; SALVAGE THERAPY; STOMATITIS; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CENTRAL NERVOUS SYSTEM NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; REMISSION INDUCTION; SALVAGE THERAPY; SURVIVAL ANALYSIS; TOPOTECAN;

EID: 33745595071     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl070     Document Type: Article

References (24)

1. Cote TR, Manns A, Hardy CR, Yellin FJ, Hartge P. Epidemiology of brain lymphoma among people with or without acquired immunodeficiency syndrome. AIDS/Cancer Study Group. J Natl Cancer Inst 1996; 88(10): 675-679.
2. Glass J, Gruber ML, Cher L, Hochberg FH. Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: Long-term outcome. J Neurosurg 1994; 81(2): 188-195.
3. Blay JY, Conroy T, Chevreau C et al. High-dose methotrexate for the treatment of primary cerebral lymphomas: Analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol 1998; 16(3): 864-871.
4. Reni M, Ferreri AJ. Therapeutic management of refractory or relapsed primary central nervous system lymphomas. Ann Hematol 2001; 80 (Suppl 3): B113-B117.
5. Abrey LE, DeAngelis LM, Yahalom J. Long-term survival in primary CNS lymphoma. J Clin Oncol 1998; 16(3): 859-863.
6. Herben VM, Bokkel Huinink WW, Beijnen JH. Clinical pharmacokinetics of topotecan. Clin Pharmacokinet 1996; 31(2): 85-102.
7. Baker SD, Heideman RL, Crom WR et al. Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors. Cancer Chemother Pharmacol 1996; 37(3): 195-202.
8. Korfel A, Oehm C, von Pawel J et al. Response to topotecan of symptomatic brain metastases of small-cell lung cancer also after whole-brain irradiation. a multicentre phase II study. Eur J Cancer 2002; 38(13): 1724-1729.
9. Grossi F, Scolaro T, Tixi L et al. The role of systemic chemotherapy in the treatment of brain metastases from small-cell lung cancer. Crit Rev Oncol Hematol 2001; 37(1): 61-67.
10. Oberhoff C, Kieback DG, Wurstlein R et al. Topotecan chemotherapy in patients with breast cancer and brain metastases: Results of a pilot study. Onkologie 2001; 24(3): 256-260.
11. Cabanillas F. The role of topoisomerase-I inhibitors in the treatment of non-Hodgkin's lymphoma. Semin Hematol 1999; 36 (4 Suppl 8): 11-15.
12. Kraut EH, Balcerzak SP, Young D et al. A phase II study of topotecan in non-Hodgkin's lymphoma: An Ohio State University phase II research consortium study. Cancer Invest 2002; 20(2): 174-179.
13. Fischer L, Thiel E, Klasen HA et al. Response of relapsed or refractory primary central nervous system lymphoma (PCNSL) to topotecan. Neurology 2004; 62(10): 1885-1887.
14. Abrey LE, Batchelor TT, Ferreri AJ et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 2005; 23(22): 5034-5043.
15. Enting RH, Demopoulos A, DeAngelis LM, Abrey LE. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology 2004; 63(5): 901-903.
16. Reni M, Mason W, Zaja F et al. Salvage chemotherapy with temozolomide in primary CNS lymphomas: Preliminary results of a phase II trial. Eur J Cancer 2004; 40(11): 1682-1688.
17. Herrlinger U, Brugger W, Bamberg M et al. PCV salvage chemotherapy for recurrent primary CNS lymphoma. Neurology 2000; 54(8): 1707-1708.
18. Arellano-Rodrigo E, Lopez-Guillermo A, Bessell EM et al. Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma. Eur J Haematol 2003; 70(4): 219-224.
19. Tyson RM, Siegal T, Doolittle ND et al. Current status and future of relapsed primary central nervous system lymphoma (PCNSL). Leuk Lymphoma 2003; 44(4): 627-633.
20. Soussain C, Suzan F, Hoang-Xuan K et al. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol 2001; 19(3): 742-749.
21. Ferreri AJ, Blay JY, Reni M et al. Prognostic scoring system for primary CNS lymphomas: The International Extranodal Lymphoma Study Group experience. J Clin Oncol 2003; 21(2): 266-272.
22. Armstrong DK. Topotecan dosing guidelines in ovarian cancer: Reduction and management of hematologic toxicity. Oncologist 2004; 9(1): 33-42.
23. Correa DD, DeAngelis LM, Shi W et al. Cognitive functions in survivors of primary central nervous system lymphoma. Neurology 2004; 62(4): 548-555.
24. Mathijssen RH, Loos WJ, Verweij J, Sparreboom A. Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan. Curr Cancer Drug Targets 2002; 2(2): 103-123.